Nektar Get Positive Data from Phase 1a Study of NKTR-192; Vivus Reports Availability of Qsymia Print
By Staff and Wire Reports   
Tuesday, 18 September 2012 19:51
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 18, 2012.

Nektar Therapeutics (Nasdaq: NKTR)
announced positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile. These data support its continued development as a new analgesic for the treatment of acute pain. The company also announced that dosing has commenced in a second single-ascending dose Phase 1a clinical study of NKTR-192, which will explore the pharmacodynamic profile of this new drug candidate in healthy subjects.


announced the U.S. market availability of Qsymia™. Qsymia is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). It is the first FDA-approved once daily combination therapy – and the first new medication available in 13 years – for the treatment of obesity.

Also Tuesday:

Applied DNA Sciences, Inc. (OTCBB: APDN)
, (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today that it has entered into a Development Agreement with Inventionland Corporation.

Celsion Corporation (NASDAQ: CLSN)
, a leading oncology drug development company, today announced that Ronnie T.P. Poon, MD, MS, PhD, FRCS (Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's pivotal, Phase III HEAT Study of ThermoDox® in primary liver cancer, discussed advancements in thermal-based treatments in cancer, including the use of ThermoDox® in combination with radiofrequency ablation (RFA), at the 2012 Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe, being held September 15-19 in Lisbon, Portugal.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
, a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for the development of its lead infectious disease drug candidates, AVI-7288 and AVI-7537, for the treatment of Marburg virus and Ebola virus, respectively.

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
today announced that consistent with the China government's review of pharmaceutical prices once a product has been included into the Reimbursement Drug List ("RDL"), the retail list price, or hospital pharmacy level price, of ZADAXIN® has been reduced by about 18% in China.

Synergetics USA, Inc. (NASDAQ: SURG)
announced today that it will release summary financial results for the fourth quarter and the fiscal year 2012 before the market opens on Monday, October 1, 2012.

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Life Sciences Conference at 8:30 a.m. ET on September 19, 2012.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus